International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Secukinumab: A Breakthrough in the Treatment of Autoimmune Diseases

V. P. Kuzhali

Assistant Professor, KMCH

Abstract:
Secukinumab is a significant advancement in the treatment of autoimmune diseases, particularly psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. By targeting interleukin-17A (IL-17A), it offers a focused approach to mitigating inflammation. This article provides a comprehensive overview of Secukinumab, exploring its mechanism of action, clinical efficacy, safety profile, administration, and ongoing research aimed at expanding its therapeutic scope.

Keywords: Secukinumab, autoimmune diseases, IL-17A, psoriasis, psoriatic arthritis, ankylosing spondylitis, biologic therapy.

Introduction:

Autoimmune diseases represent a complex and often debilitating group of conditions in which the immune system erroneously attacks the body's own tissues. These diseases, including rheumatoid arthritis, psoriasis, and ankylosing spondylitis, can lead to chronic inflammation, significant pain, and permanent tissue damage.

Traditional treatments for autoimmune diseases involve broad-spectrum immunosuppressive agents like corticosteroids, which can reduce inflammation but carry significant risks, including increased susceptibility to infections and a host of side effects. The development of biologic therapies, such as Secukinumab, has shifted the focus towards targeted treatment strategies, minimizing adverse effects while maximizing therapeutic benefits.[1]

Secukinumab is a monoclonal antibody designed to specifically target IL-17A, a critical cytokine in the inflammatory pathway.[2] Its specificity has made it a valuable tool in managing autoimmune diseases, offering significant efficacy with a more manageable safety profile compared to traditional treatments.

Mechanism of Action:

IL-17A is a pro-inflammatory cytokine produced by various immune cells, most notably T-helper 17 (Th17) cells (Fig 1). It plays a key role in promoting inflammation by stimulating the production of other pro-inflammatory cytokines, recruiting neutrophils, and promoting tissue damage. IL-17A is a significant driver of the inflammatory process in several autoimmune diseases, making it an attractive target for therapeutic intervention.[3,4]

Secukinumab binds to IL-17A with high affinity, blocking its interaction with IL-17 receptors on target cells.[5] This interruption in the signaling pathway reduces inflammation and its associated symptoms, allowing for effective management of autoimmune diseases. The specificity of this approach

distinguishes Secukinumab from broader immunosuppressive agents, as it focuses on a singular, critical pathway rather than suppressing the entire immune response.



Fig 1: Secukinumab - Mechanism of action

Clinical Efficacy:

Secukinumab has demonstrated significant clinical efficacy across multiple autoimmune diseases. Let's examine the evidence supporting its use in each approved indication.

Psoriasis:

Psoriasis is a chronic autoimmune disease characterized by the rapid proliferation of skin cells, leading to the formation of red, scaly plaques on the skin. It can significantly impact a person's quality of life, causing itching, pain, and social discomfort.

Secukinumab has been a breakthrough treatment for moderate to severe plaque psoriasis[6]. In pivotal phase III clinical trials like ERASURE and FIXTURE[7], Secukinumab outperformed placebo and other standard therapies, with a high proportion of patients achieving a 75% reduction in the Psoriasis Area and Severity Index (PASI 75). Many patients reached PASI 90 or even PASI 100, indicating near-complete or complete skin clearance. A clinical study shows the improvement in Psoriasis on treating with Secukinumab (Fig 2).[8]

The rapid onset of action and durability of response are notable. Patients experienced significant improvement within weeks of starting treatment, and these benefits were maintained over long-term follow-up periods. This sustained efficacy is crucial for a condition like psoriasis, where chronicity and relapse are common concerns.





Fig 2: Clinical improvement in Psoriasis patients with Secukinumab

Psoriatic Arthritis:

Psoriatic arthritis is a complex condition that involves joint inflammation and skin lesions characteristic of psoriasis. It can lead to joint pain, stiffness, swelling, and even permanent joint damage if not adequately treated.

Secukinumab has shown considerable efficacy in treating psoriatic arthritis.[9] Clinical trials such as FUTURE 1 and FUTURE 2[10] revealed that Secukinumab significantly reduced joint symptoms and improved physical function. Patients reported reduced pain, stiffness, and swelling, along with improvements in dactylitis (swelling of fingers and toes) and enthesitis (inflammation at tendon insertion points). Also, Secukinumab 300 mg decreases the depression level in patients with Psoriatic Arthritis (Fig 3).[11]



Fig 3: Secukinumab 300 mg and depression in Psoriatic arthritis patients

Furthermore, Secukinumab demonstrated the ability to slow the radiographic progression of joint damage, a critical factor in preserving joint function and preventing deformity. The drug's efficacy as monotherapy and in combination with methotrexate provides flexibility for clinicians in tailoring treatment to individual patient needs.

Ankylosing Spondylitis:

Ankylosing spondylitis (AS) is a type of axial spondyloarthritis that primarily affects the spine, causing chronic inflammation, pain, stiffness, and potentially leading to spinal fusion. It can significantly impact a patient's mobility and quality of life.

Secukinumab has become an essential treatment for AS, with clinical trials like MEASURE 1 and MEASURE 2[12] demonstrating significant reductions in disease activity. Patients experienced improved spinal mobility, reduced pain, and enhanced quality of life. The drug's ability to prevent radiographic progression of spinal damage is particularly important, as spinal fusion can lead to severe limitations in mobility. Secukinumab Demonstrates Rapid and Sustained Efficacy in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels (Fig 4).[13]



Fig 4: Improvement in ASAS40 Response rate in patients with Normal/ Elevated CRP at Baseline through Week 156 (Secukinumab and Placebo Comparison)

Non-Radiographic Axial Spondyloarthritis:

Secukinumab's approval for non-radiographic axial spondyloarthritis (nr-axSpA)[14] has expanded its therapeutic scope. This condition, while similar to AS, lacks visible radiographic damage but still presents with significant inflammation and symptoms.

The PREVENT trial provided strong evidence of Secukinumab's efficacy in treating nr-axSpA. Patients experienced reduced symptoms, improved physical function, and a better quality of life. This approval highlights the versatility of Secukinumab in managing various forms of axial spondyloarthritis.[15]

Safety Profile:

While Secukinumab has shown considerable efficacy, its safety profile is a crucial consideration. The most common adverse events associated with Secukinumab are mild to moderate in severity. These include upper respiratory tract infections, headache, injection site reactions, and diarrhea. In most cases, these side effects are manageable with supportive care or mild interventions.

Risks of Serious Infections:
Given its targeted immunosuppressive nature, Secukinumab carries a risk of serious infections, including opportunistic infections and reactivation of latent tuberculosis. Patients should be monitored closely for signs of infection, and pre-treatment screening for tuberculosis is recommended. Although the overall risk of serious infections is relatively low, vigilance is required, particularly in patients with underlying health conditions or compromised immune systems.

Long-Term Safety and Immunogenicity:
Long-term safety is a critical concern with biologic therapies like Secukinumab.[16] Although rare, some patients may develop antibodies against the drug, potentially reducing its efficacy or leading to hypersensitivity reactions. Long-term surveillance and post-marketing studies are essential to understand the broader safety profile and detect any rare adverse events that may arise over time.

Administration and Dosage:
Secukinumab is administered via subcutaneous injection, providing flexibility for patients who can self-administer the drug. It is available in pre-filled syringes or autoinjectors, allowing for convenient administration at home. The dosing regimen varies depending on the condition being treated:
Psoriasis: The initial dose is 300 mg at weeks 0, 1, 2, 3, and 4, followed by 300 mg every four weeks thereafter.
Psoriatic Arthritis: The typical dose is 150 mg at similar intervals, with an option for 300 mg for more severe cases or when used in combination with other therapies.[17]
Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: The standard dose is 150 mg every four weeks.
The flexibility in dosing and the ease of administration contribute to patient adherence and overall treatment success.

Future Directions:
Secukinumab's success in treating psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis has opened the door to further research and broader applications. Clinical trials are exploring the use of Secukinumab in additional autoimmune diseases, such as rheumatoid arthritis,[18] hidradenitis suppurativa, and lupus. The success of these trials could expand the therapeutic scope of Secukinumab, providing new treatment options for a broader range of patients.

Combination Therapies and Personalized Medicine:
Researchers are investigating the potential for combination therapies with other biologics or conventional treatments to improve outcomes and reduce risks. Personalized medicine, where treatment is tailored to individual patient characteristics and immune profiles, holds promise for optimizing therapeutic benefits and minimizing adverse events.

Real-World Evidence and Long-Term Studies:
Real-world evidence and long-term studies are critical for understanding the broader safety and efficacy of Secukinumab. These studies provide valuable insights into how the drug performs in diverse patient populations and under real-world conditions, which may differ from controlled clinical trials. Long-term

studies also offer data on the sustainability of therapeutic benefits and the risk of any long-term adverse events.

Conclusion:

Secukinumab has significantly transformed the treatment landscape for several autoimmune diseases, offering a targeted approach with proven efficacy and a manageable safety profile. Its role in managing conditions like psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis is well-established, providing hope and improved quality of life for many patients. As research continues, Secukinumab's impact on autoimmune disease management is poised to grow, leading to new possibilities for effective and safe treatment.

References:

1. Kirkham BW., et al. (2014). The Autoimmune Diseases and Autoinflammatory Syndromes. In Firestein GS, Budd RC, Gabriel SE, McInnes IB. O'Dell JR, eds. Kelley's Textbook of Rheumatology. 9th edition. Saunders Elsevier.
2. Brembilla NC., et al. (2017). Role of IL-17A in Autoimmune and Inflammatory Diseases. Advances in Experimental Medicine and Biology, 1024, 141-159.
3. Yamamura M., et al. (2001). Production of IL-17 by Synovial T Cells in Rheumatoid Arthritis and its Induction of IL-6, IL-8, and GM-CSF by Synoviocytes. The Journal of Immunology, 166(3), 1955-1960.
4. Martin DA., et al. (2013). Secukinumab Inhibits IL-17A and IL-17F in Patients with Psoriasis. The Journal of Immunology, 191(2), 349-360.
5. Richards H.B., et al. (2001). Interleukin-17 in Systemic Autoimmune Diseases. Journal of Clinical Immunology, 21(5), 444-451.
6. Langley RG., et al. (2014). Secukinumab in Plaque Psoriasis — Results of a Phase 3 Randomized Controlled Trial. The New England Journal of Medicine, 371(4), 326-338.
7. Blauvelt A., et al. (2015). Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials. The New England Journal of Medicine, 372(2), 111-121.
8. Zeng J, Luo Q, Wen J, et al (2020). Real-world investigation of the efficacy and safety of secukinumab for psoriasis treatment in a Chinese population. Chinese Medical Journal/Chinese Medical Journal. 134(1):117-119.
9. Gossec L., et al. (2020). EULAR Recommendations for the Management of Psoriatic Arthritis with a Focus on Biologics. Annals of the Rheumatic Diseases, 79(6), 700-712.
10. McInnes IB., et al. (2015). Secukinumab, a Human Anti–Interleukin-17A Monoclonal Antibody, in Psoriatic Arthritis. The New England Journal of Medicine, 373(14), 1329-1339.
11. Mease, P., et al. (2017). Secukinumab Treatment of Psoriatic Arthritis and Moderate to Severe Psoriasis Relieves Anxiety/Depression Up to 52 Weeks: An Overview From Secukinumab Phase 3 Clinical Trials. Arthritis & Rheumatology, 69 (Suppl 10), 607.
12. Baeten D., et al. (2015). Secukinumab in Ankylosing Spondylitis — Results of Two Phase 3 Randomized Controlled Trials. The New England Journal of Medicine, 373(26), 2534-2548.
13. Braun J., et al. (2017). Secukinumab Demonstrates Rapid and Sustained Efficacy in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels: Pooled Analysis of Two Phase 3 Studies. American College of Rheumatology; 69.

14. Deodhar A., et al. (2019). Secukinumab in Non-Radiographic Axial Spondyloarthritis. The Lancet, 394(10198), 2107-2119.
15. Braun J., et al. (2018). 2018 Update of the ASAS-EULAR Management Recommendations for Axial Spondyloarthritis. Annals of the Rheumatic Diseases, 78(6), 774-781.
16. Menter A., et al. (2017). Treatment Guidelines for Psoriasis with Biologics. Journal of the American Academy of Dermatology, 76(4), 661-668.
17. Villaseñor T., et al. (2019). Use of Biologics in Psoriasis and Psoriatic Arthritis: An Update. Clinics in Dermatology, 37(6), 507-511
18. Choy EH., et al. (2014). Biologics and Small Molecule Inhibitors in Rheumatoid Arthritis. Nature Reviews Rheumatology, 10(1), 5-11.